Center Laboratories Total Assets
Center Laboratories total assets. Based on the latest financial reports, Center Laboratories (4123) holds total assets worth NT$25.81 Billion TWD (≈ $813.14 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 4123 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Center Laboratories (2006–2024)
Total assets of Center Laboratories from 2006 to 2024. This chart illustrates how Center Laboratories's total assets have evolved over time, based on quarterly financial data. See 4123 stock price and chart for real-time trading data and today's change.
Center Laboratories - Asset Composition Analysis
Center Laboratories Total Assets Breakdown (December 2024)
Center Laboratories total assets breakdown as of December 2024. Center Laboratories's total assets of NT$25.81 Billion consist of 14.8% current assets and 85.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 5.7% |
| Accounts Receivable | NT$178.58 Million | 0.7% |
| Inventory | NT$309.70 Million | 1.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Center Laboratories's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 4123 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Center Laboratories's current assets represent 14.8% of total assets in 2024, a decrease from 57.5% in 2006.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2024, down from 13.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 1.2% of total assets.
Center Laboratories Competitors by Total Assets
Key competitors of Center Laboratories based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Center Laboratories - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.51 | 0.96 | 0.52 |
| Quick Ratio | 0.42 | 0.89 | 0.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$-1.86 Billion | NT$-144.39 Million | NT$-1.32 Billion |
Center Laboratories - Advanced Valuation Insights
This section examines the relationship between Center Laboratories's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.47 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -5.4% |
| Total Assets | NT$25.54 Billion |
| Market Capitalization | $653.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Center Laboratories's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Center Laboratories's assets decreased by 5.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Center Laboratories (2006–2024)
The table below shows the annual total assets of Center Laboratories from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$25.54 Billion ≈ $804.56 Million |
-5.43% |
| 2023-12-31 | NT$27.00 Billion ≈ $850.72 Million |
+7.20% |
| 2022-12-31 | NT$25.19 Billion ≈ $793.55 Million |
-17.26% |
| 2021-12-31 | NT$30.44 Billion ≈ $959.14 Million |
+9.25% |
| 2020-12-31 | NT$27.87 Billion ≈ $877.97 Million |
+21.87% |
| 2019-12-31 | NT$22.87 Billion ≈ $720.38 Million |
+12.21% |
| 2018-12-31 | NT$20.38 Billion ≈ $641.97 Million |
-46.80% |
| 2017-12-31 | NT$38.30 Billion ≈ $1.21 Billion |
+26.17% |
| 2016-12-31 | NT$30.35 Billion ≈ $956.35 Million |
+8.75% |
| 2015-12-31 | NT$27.91 Billion ≈ $879.41 Million |
+190.27% |
| 2014-12-31 | NT$9.62 Billion ≈ $302.96 Million |
+75.97% |
| 2013-12-31 | NT$5.46 Billion ≈ $172.17 Million |
+34.03% |
| 2012-12-31 | NT$4.08 Billion ≈ $128.45 Million |
+56.10% |
| 2011-12-31 | NT$2.61 Billion ≈ $82.29 Million |
+6.55% |
| 2010-12-31 | NT$2.45 Billion ≈ $77.23 Million |
+1.50% |
| 2009-12-31 | NT$2.42 Billion ≈ $76.09 Million |
+137.67% |
| 2008-12-31 | NT$1.02 Billion ≈ $32.02 Million |
+56.62% |
| 2007-12-31 | NT$648.84 Million ≈ $20.44 Million |
+30.92% |
| 2006-12-31 | NT$495.58 Million ≈ $15.61 Million |
-- |
About Center Laboratories
Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antituss… Read more